WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, July 21, 2016

FoxFeed Blog: Piece of the Alpha-synuclein Puzzle Revealed

By Loren DeVito PhDJuly 21, 2016


Research on alpha-synuclein, a lead target for therapy to slow or stop Parkinson’s and potential marker of disease progression, is quickly advancing, and scientists are learning more about this protein’s role in Parkinson’s disease (PD). Recently, researchers discovered how this protein damages neurons in PD, revealing new potential strategies for developing neuroprotective therapies.
A group of researchers led by  J. Timothy Greenamyre, MD, PhD, director of the Pittsburgh Institute for Neurodegenerative Diseases (PIND), studied the interaction between alpha-synuclein and mitochondria using pre-clinical models of Parkinson’s. 
Previous studies showed that mitochondria, mini “powerhouses” in the cell that produce energy, are dysfunctional in PD and may be related to alpha-synuclein. However, their direct interaction was not well understood until now.
The researchers found that certain types of the alpha-synuclein protein bind to mitochondria and impair energy production in dopamine neurons, as reported in Science Translational Medicine. Dr. Greenamyre and his colleagues also identified potential ways to prevent toxicity by protecting mitochondria from alpha-synuclein binding using specific proteins. Their results were then confirmed using samples of brain tissue from individuals who had PD.
“These results are very promising for several reasons. First, it identifies a very specific mechanism by which altered forms of alpha-synuclein cause mitochondria in neurons to function sub-optimally. Second, it identifies specific forms of alpha-synuclein that are toxic to mitochondria,” said Dr. Greenamyre, who is also a member of the scientific advisory board at The Michael J. Fox Foundation (MJFF). “In addition, these findings help explain why dopamine neurons are so vulnerable to degeneration in PD.” 
Funding studies on alpha-synuclein is a major priority of our MJFF strategy (although the Foundation did not fund this particular study). In addition to funding the development of therapies that target alpha-synuclein, we also support research into the biology of alpha-synuclein and how to measure alpha-synuclein levels. Our most recent effort aims to qualify alpha-synuclein as a biomarker for PD by standardizing the way it is measured. 
More research is needed to determine how new therapeutic strategies based on this study could help individuals with PD. “These findings suggest several new approaches to protect neurons from alpha-synuclein toxicity – and these are being tested now in models of PD,” added Dr. Greenamyre.
https://www.michaeljfox.org/foundation/news-detail.php?another-piece-of-the-alpha-synuclein-puzzle-revealed

No comments:

Post a Comment